ArticleFrontiers in medicine2026

Efficacy and safety in the short-to-intermediate term of advanced combination therapy with upadacitinib for refractory Crohn's disease: real-world evidence from eastern China.

Zhen-Yu Ye et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.